Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Capital Expenditures (2019 - 2025)

Pulmonx (LUNG) has disclosed Capital Expenditures for 7 consecutive years, with $364000.0 as the latest value for Q3 2025.

  • Quarterly Capital Expenditures rose 385.33% to $364000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Sep 2025, up 65.19% year-over-year, with the annual reading at $1.4 million for FY2024, 79.31% up from the prior year.
  • Capital Expenditures for Q3 2025 was $364000.0 at Pulmonx, up from $66000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $2.6 million in Q4 2021, with the low at -$393000.0 in Q3 2023.
  • Average Capital Expenditures over 5 years is $357315.8, with a median of $242000.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 1100.0% in 2023, while the deepest fall reached 2907.14% in 2023.
  • Over 5 years, Capital Expenditures stood at $2.6 million in 2021, then plummeted by 102.88% to -$75000.0 in 2022, then skyrocketed by 1100.0% to $750000.0 in 2023, then skyrocketed by 60.4% to $1.2 million in 2024, then plummeted by 69.74% to $364000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $364000.0, $66000.0, and $9000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.